Takeda Pharma has joined the Structural
Genomics Consortium to fund collective drug research aimed at bringing new,
more effective medicines to market faster.
Takeda
Pharmaceutical Company Limited has joined theStructural Genomics Consortium (SGC)
to fund collective drug research aimed at bringing new, more effective
medicines to market faster.
The
SGC, a not-for-profit organization based at the Universities of Toronto,
Canada, and Oxford, England, supports the discovery of new medicines by more
than 200 scientists from academia and industry who make all early-stage
research openly available with no patents or restrictions.
Takeda’s
contribution raises the total from US$13 million to US$50 million in support of
the SGC by six of the world’s leading pharmaceutical companies. Takeda will
also participate on the SGC Scientific Committee and its Board of Directors.
“As a
global leader in research, Takeda is dedicated to helping change the way drug
discovery is conducted,” said Paul Chapman, General Manager, Pharmaceutical
Research Division, Takeda.
“We are
very excited about the opportunity to become a part of the SGC, and firmly
believe that important new medicines will be discovered in industry and vital
scientific knowledge will be gained in academia through this open innovation.”
Source: Takeda
Pharmaceutical Co.
No comments:
Post a Comment